A Phase 2 interventional study of Eteplirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Terminated at 4 sites in 4 countries. Open to male participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2023-08-18.
Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 9th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 5 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2019.
This study's enrollment of 15 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 16th registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have successfully completed the 96-week eteplirsen Study 4658-102.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.
Drug: Eteplirsen
Eteplirsen IV infusion once weekly.
Also known as: AVI-4658, EXONDYS 51, EXONDYS
Number of Participants Experiencing Adverse Events (AEs)
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
Time frame: Up to 162 weeks
Number of Participants Experiencing Death Due to Adverse Events
A summary of all deaths regardless of causality is located in the 'Reported Adverse Events' section.
Time frame: Up to 162 weeks
Number of Participants Experiencing Adverse Events of Special Interest (AESIs)
AESIs were defined as any AE that was of scientific and medical concern specific to study treatment, for which ongoing and rapid communication by the Investigator to the sponsor was appropriate. AESIs included findings potentially indicative of hepatic and renal abnormalities, hypersensitivity, and thrombocytopenia. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
Time frame: Up to 162 weeks
In an effort to reduce clinical trial burden on participants while ensuring continued treatment if desired, pending commercial availability of eteplirsen, participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment.
| Milestone | Eteplirsen |
|---|---|
| Started | 15 |
| Received at least 1 dose of study drug | 15 |
| Completed | 0 |
| Not completed | 15 |
| Withdrew: Transitioned to another sarepta study | 2 |
| Withdrew: Study terminated by sponsor | 12 |
| Withdrew: Withdrawal by subject | 1 |
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
| Participants | Eteplirsen |
|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 15 |
A summary of all deaths regardless of causality is located in the 'Reported Adverse Events' section.
| Participants | Eteplirsen |
|---|---|
| Number of Participants Experiencing Death Due to Adverse Events | 0 |
AESIs were defined as any AE that was of scientific and medical concern specific to study treatment, for which ongoing and rapid communication by the Investigator to the sponsor was appropriate. AESIs included findings potentially indicative of hepatic and renal abnormalities, hypersensitivity, and thrombocytopenia. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
| Participants | Eteplirsen |
|---|---|
| Number of Participants Experiencing Adverse Events of Special Interest (AESIs) | 0 |
Collected over Up to 162 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eteplirsen | 0/15 (0%) | 1/15 (6.7%) | 14/15 (93.3%) |
| Event | Eteplirsen |
|---|---|
| InfluenzaInfections and infestations | 1/15 |
| Event | Eteplirsen |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 12/15 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 9/15 |
| PyrexiaGeneral disorders | 9/15 |
| NasopharyngitisInfections and infestations | 8/15 |
| Corona virus infectionInfections and infestations | 7/15 |
| RhinitisInfections and infestations | 6/15 |
| HeadacheNervous system disorders | 6/15 |
| ConstipationGastrointestinal disorders | 5/15 |
| VomitingGastrointestinal disorders | 5/15 |
| ContusionInjury, poisoning and procedural complications | 5/15 |
Safety Set: all participants who received eteplirsen.
| Age, Continuous(years) | Eteplirsen |
|---|---|
| Mean | 3.7 ± 1.10 |
| Sex: Female, Male(Participants) | Eteplirsen |
|---|---|
| Female | 0 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Eteplirsen |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 8 |
| Race (NIH/OMB)(Participants) | Eteplirsen |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Aug 2022, 38 months.
Results were first posted in Aug 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →